SCHEMBL4760693

SCHEMBL4760693

O=C1CCN(C(=O)c2cccc(N3Cc4cccc(Cl)c4C3=O)c2)CC1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 1/20 0.66
EGFR P00533 2/20 0.46
PARP1 P09874 2/20 0.42
ALDH1A1 P00352 3/20 0.42
GAA P10253 1/20 0.42
HTR2A P28223 2/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
GRM1 Q13255 1/20 0.42
TSHR P16473 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
USP2 O75604 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716862 0.87 BDKRB1 (0.64) BDKRB1EGFRPARP1ALDH1A1GAA
SCHEMBL4716396 0.85 BDKRB1 (0.61) BDKRB1EGFRPARP1HTR2AHTR2C
SCHEMBL5630639 0.84 BDKRB1 (0.61) BDKRB1EGFRPARP1HTR2AHTR2C
SCHEMBL4716342 0.84 BDKRB1 (0.77) BDKRB1EGFRPARP1ALDH1A1HTR2A
SCHEMBL4714835 0.83 BDKRB1 (0.60) BDKRB1EGFRPARP1HTR2AHTR2C
SCHEMBL4716223 0.83 BDKRB1 (0.67) BDKRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL4714259 0.83 BDKRB1 (0.60) BDKRB1PARP1ALDH1A1GAATSHR
SCHEMBL4759441 0.83 BDKRB1 (0.84) BDKRB1ALDH1A1TSHRHPGDSMN1; SMN2
SCHEMBL4714572 0.83 BDKRB1 (0.59) BDKRB1
SCHEMBL4717762 0.83 BDKRB1 (0.74) BDKRB1USP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US claimed
EP-1877401-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM Elan Pharmaceuticals Inc. (US) 2008-01-16 EP disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 BDKRB1 1/4885EGFR 2482/4885PARP1 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.